U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C20H32N6O12S2
Molecular Weight 612.631
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of OXIGLUTATIONE

SMILES

N[C@@H](CCC(=O)N[C@@H](CSSC[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)NCC(O)=O)C(=O)NCC(O)=O)C(O)=O

InChI

InChIKey=YPZRWBKMTBYPTK-BJDJZHNGSA-N
InChI=1S/C20H32N6O12S2/c21-9(19(35)36)1-3-13(27)25-11(17(33)23-5-15(29)30)7-39-40-8-12(18(34)24-6-16(31)32)26-14(28)4-2-10(22)20(37)38/h9-12H,1-8,21-22H2,(H,23,33)(H,24,34)(H,25,27)(H,26,28)(H,29,30)(H,31,32)(H,35,36)(H,37,38)/t9-,10-,11-,12-/m0/s1

HIDE SMILES / InChI

Molecular Formula C20H32N6O12S2
Molecular Weight 612.631
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Oxiglutathione is the oxidized disulfide form of glutathione (GSH) with potential protective activity. Glutathione disulfide (GSSG) is reduced by glutathione reductase to GSH. GSSG and GSH together play important roles in numerous redox reactions, such as those involved in the detoxification of harmful substances and free radicals, and in reactions preventing oxidative damage in erythrocytes. Upon ocular administration in irrigation solution, glutathione disulfide may exert a beneficial effect on the intracellular redox state of glutathione, thereby protecting the integrity and barrier function of the corneal endothelial cells.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
NAVSTEL

Cmax

ValueDoseCo-administeredAnalytePopulation
0.65 μg/mL
250 mg/kg single, intraperitoneal
OXIGLUTATIONE plasma
Mus musculus

AUC

ValueDoseCo-administeredAnalytePopulation
1.18 μg × h/mL
250 mg/kg single, intraperitoneal
OXIGLUTATIONE plasma
Mus musculus

T1/2

ValueDoseCo-administeredAnalytePopulation
13 min
250 mg/kg single, intraperitoneal
OXIGLUTATIONE plasma
Mus musculus

Doses

AEs

Sourcing

PubMed

Patents

Sample Use Guides

In Vivo Use Guide
NAVSTEL solution, should be used according to the standard technique employed by the operating surgeon. Do not use NAVSTEL until Part I is fully reconstituted with Part II. Reconstitute just prior to surgery. After reconstitution, use a single patient administration set with an air-inlet in the plastic spike since the bottle does not contain a separate airway tube. Follow the directions for the particular administration set to be used. Insert the spike aseptically into the bottle through the center target area of the rubber stopper. Allow the fluid to flow to remove air from the tubing before intraocular irrigation begins. If a second bottle is necessary to complete the surgical procedure, insure that the vacuum is vented from the second bottle BEFORE attachment to the administration set.
Route of Administration: Irrigation
In Vitro Use Guide
Kinetic studies were carried out at 25 °C in a volume of 1 mL. The assay mixtures contained 100 mM potassium phosphate buffer pH 7.0, 200 mM KCl, 100 uM NADPH, and 1 mM GSSG. Inhibitor stock solutions were prepared in 100% DMSO. One % final DMSO concentration was kept constant in the assay cuvette. The reaction was started with the addition of the enzyme (8 milliunits or 1.2 pmol of FAD-containing subunit in 5 uL aliquot), and initial rates were determined from NADPH oxidation measured at 340 nm. Km for GSSG reduction was found to be 12.5 uM.
Substance Class Chemical
Record UNII
ULW86O013H
Record Status Validated (UNII)
Record Version